Cancer does not arise from a single catastrophic event inside a cell. It develops through a slow, multistep accumulation of genetic and chemical changes that, one by one, strip away the safeguards that keep cell growth in check. Experimental models suggest that a normal cell needs at least four or more distinct heritable changes before it becomes fully cancerous. That process can take years or decades, which is part of why cancer risk climbs with age and why the transformation is so difficult to catch in its earliest stages.
The Multistep Model
The idea that cancer requires multiple hits to a cell’s control systems dates back decades, but the experimental evidence is now detailed enough to name specific types of damage. In cell culture models, researchers have shown that a normal cell must gain activation of growth-promoting genes and lose tumor-suppressing genes before it can behave like a cancer cell. In one well-studied hamster model, full transformation required activation of two oncogenes and loss of two tumor suppressor genes.1PubMed Central. Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene Human cancers appear to follow the same logic, though they often accumulate even more mutations along the way.
Oncogenes are mutated versions of normal genes called proto-oncogenes. In their unmutated state, proto-oncogenes help regulate cell growth and division in an orderly way. When a mutation locks one of these genes into an “always on” position, the cell receives a constant signal to grow and divide. In colon cancer, for example, researchers have found that a single amino acid change in the RET proto-oncogene can trigger the protein to form abnormal pairs and send growth-promoting signals, boosting cell proliferation and migration.1PubMed Central. Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene
Tumor suppressor genes work on the opposite side of the equation. They act as brakes, slowing division when something is wrong or triggering damaged cells to self-destruct. The most famous is TP53, which encodes the p53 protein. p53 coordinates the cell’s response to DNA damage by halting division and, if the damage is irreparable, ordering cell death. When both copies of TP53 are lost or mutated, that brake disappears entirely. Research into p53 continues to reveal new layers of complexity: some mutations do not merely silence the gene but give the altered protein entirely new functions that actively promote cancer.2PubMed Central. The Evolution of TP53 Mutations: From Loss-of-Function to Separation-of-Function Mutants
Changes That Do Not Touch the DNA Sequence
Mutations are not the only way cells lose control. Epigenetic changes alter how genes are read without changing the underlying DNA code. These modifications include chemical tags added to DNA itself, changes to the proteins that DNA wraps around, and small RNA molecules that silence specific genes. When these systems go haywire, a tumor suppressor gene can be shut off as effectively as if it had been deleted, or a growth-promoting gene can be cranked up without any mutation at all.3PubMed Central. Epigenetic modifications in cancer
What makes epigenetic disruption especially important is timing. These changes appear to occur very early in cancer development, sometimes before obvious genetic mutations have piled up. They are also heritable from one cell generation to the next, meaning a daughter cell inherits the same muted tumor suppressor its parent had. Unlike mutations, though, epigenetic changes are reversible in principle, which has made them a focus of drug development.4Genes & Diseases. Epigenetics: Mechanisms, potential roles, and therapeutic strategies in cancer progression
How Cancer Cells Cheat Death
Normal cells have a built-in limit on how many times they can divide. Each time a cell copies its DNA, the protective caps on the ends of chromosomes, called telomeres, get a little shorter. Eventually they become too short to protect the DNA, and the cell stops dividing or dies. Cancer cells bypass this limit by switching on an enzyme called telomerase, which rebuilds those caps after each division. In most cancers, telomerase activity is what grants cells their ability to keep dividing indefinitely.5PubMed. Telomere maintenance mechanisms in cancer: telomerase, ALT or lack thereof A smaller subset of cancers use an alternative mechanism to maintain telomeres without telomerase, but the outcome is the same: the cell becomes effectively immortal.6PubMed Central. Telomerase in Cancer: Function, Regulation, and Clinical Translation
Cells also have a self-destruct program called apoptosis that activates when something goes seriously wrong, like severe DNA damage or loss of normal growth signals. In a healthy body, apoptosis quietly eliminates billions of damaged or unneeded cells every day. Cancer cells learn to block this program. They can overproduce survival signals, undermine the proteins that execute cell death, or disable the sensors that detect damage in the first place. This resistance to apoptosis is not just a feature of cancer; it is also one of the main reasons tumors resist treatment, since radiation and many chemotherapy drugs work by trying to trigger this self-destruct pathway.7PubMed. Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck
Rewired Metabolism and New Blood Vessels
Rapidly dividing cells need raw materials, and cancer cells solve that problem by overhauling how they process fuel. Normal cells rely heavily on oxygen-dependent energy production, which is efficient. Cancer cells, even when oxygen is available, shift toward a less efficient strategy that ferments glucose into lactate. This quirk, known as the Warburg effect, seems counterintuitive because it wastes energy. But the tradeoff buys the cell something more valuable: the chemical building blocks needed to manufacture new DNA, membranes, and proteins at high speed.8PubMed Central. The Warburg Effect: How Does it Benefit Cancer Cells? This metabolic switch also gives cancer cells an advantage in the low-oxygen, nutrient-poor interior of a growing tumor.9Critical Reviews in Oncology/Hematology. Novel insight into the Warburg effect: Sweet temptation
The switch toward glycolysis is not accidental. It is driven by the same oncogene activation and tumor suppressor loss that caused uncontrolled growth in the first place, along with signals from the low-oxygen conditions inside a growing mass.10PubMed. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression
As a tumor grows beyond a millimeter or so in size, it outstrips the oxygen and nutrients available from nearby blood vessels. To keep growing, it must recruit its own blood supply, a process called angiogenesis. Cancer cells do this by releasing signaling molecules, especially vascular endothelial growth factor (VEGF), which coax nearby blood vessels to sprout new branches toward the tumor. Low oxygen levels inside the tumor trigger a sensor protein called HIF-1α, which in turn ramps up VEGF production. Blocking this signaling chain has been shown to reduce tumor blood vessel formation in laboratory studies.11PubMed. Hypoxia inducible factor-1α/vascular endothelial growth factor signaling activation correlates with response to radiotherapy and its inhibition reduces hypoxia-induced angiogenesis in lung cancer
The Supportive Neighborhood Around a Tumor
A tumor is not just a clump of cancer cells. It sits within a complex local environment made up of normal cells, connective tissue, immune cells, and blood vessels, all of which can be co-opted to support cancer growth. Among the most influential collaborators are cancer-associated fibroblasts (CAFs), which are normal connective tissue cells that have been reprogrammed by signals from the tumor. CAFs remodel the physical scaffolding around the tumor, secreting structural proteins and enzymes that reshape the surrounding tissue in ways that help cancer cells move and survive.12PubMed Central. Cancer-Associated Fibroblasts: Master Tumor Microenvironment Modifiers The biochemical cross-talk between cancer cells and CAFs, along with the physical remodeling they carry out, is a major contributor to how tumors become capable of spreading to distant organs.13Biochemical Society Transactions. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis
The immune system is supposed to be the body’s last line of defense against rogue cells, and it does destroy abnormal cells routinely. But established tumors have usually found ways to suppress that response. Chronic inflammation within the tumor environment attracts immune-suppressive cells and activates molecular checkpoints that tell attacking immune cells to stand down.14PubMed Central. Immunosuppression associated with chronic inflammation in the tumor microenvironment Inflammatory signaling can even help tumors hide from cytotoxic T cells, the immune system’s most potent cancer killers. Research has shown that reducing certain inflammatory signals in tumor cells may be enough to make them visible to immune attack again.15Science Signaling. Inflammation helps tumors evade immune detection Modern immunotherapy drugs work by releasing these brakes, essentially giving the immune system permission to attack the tumor.
Breaking Free and Spreading
The deadliest feature of cancer is metastasis, the ability to leave the original tumor, travel through the bloodstream or lymphatic system, and colonize distant organs. For a cell anchored in a tissue to do this, it has to undergo a dramatic identity shift. Researchers call it the epithelial-to-mesenchymal transition, or EMT. During EMT, a cell that was tightly bound to its neighbors loosens those connections, changes shape, and gains the ability to move through surrounding tissue. This same program operates during normal embryonic development and wound healing, but in cancer it is hijacked to enable invasion.16PubMed Central. Epithelial-Mesenchymal Transition in Cancer: A Historical Overview
Recent work has complicated the picture by revealing that EMT is not a single program. Cancer cells can activate at least two distinct versions: one that resembles the embryonic program and drives physical movement, and another that triggers inflammation. These two trajectories appear in separate populations of tumor cells, suggesting that a tumor can simultaneously pursue invasion and immune manipulation through the same underlying cellular machinery.17Nature Cancer. Two distinct epithelial-to-mesenchymal transition programs control invasion and inflammation in segregated tumor cell populations
What Triggers the First Damage
If carcinogenesis requires multiple hits to a cell’s control systems, what causes those initial injuries? The triggers fall into three broad categories: chemicals, viruses, and radiation.
Chemical carcinogens, or their breakdown products inside the body, cause cancer by physically attaching to DNA, forming structures called adducts. These adducts distort the DNA molecule and can cause errors when the cell tries to copy it. The body also generates its own DNA-damaging molecules through normal metabolism and oxidative stress.18PubMed Central. DNA adducts: Formation, biological effects, and new biospecimens for mass spectrometric measurements in humans DNA damage alone, however, is not the whole story. Decades of research have established that adduct formation is “necessary but not sufficient” for cancer. Many additional factors, including the cell’s repair capacity, the tissue’s inflammatory state, and whether the mutation hits a critical gene, determine whether that initial damage ever progresses further.19PubMed. Linking DNA adduct formation and human cancer risk in chemical carcinogenesis
Certain viruses push cells toward cancer by more direct routes. DNA tumor viruses often produce proteins that disable the cell’s key tumor suppressors, especially p53 and the retinoblastoma protein (pRB), effectively removing two major brakes at once.20PubMed Central. Viral carcinogenesis: factors inducing DNA damage and virus integration Some viruses also insert their own DNA directly into the human genome, disrupting genes near the insertion site. Hepatitis B virus (HBV), for instance, preferentially inserts near gene-control regions, and one of its proteins, HBx, extends a phase of the cell cycle in ways that promote chromosomal instability and eventually liver cancer.21Signal Transduction and Targeted Therapy. Viral oncogenesis in cancer: from mechanisms to therapeutics
Ionizing radiation, whether from ultraviolet light, medical imaging, or environmental exposure, damages DNA by breaking both strands of the double helix simultaneously. These double-strand breaks are the most dangerous form of DNA damage because they are the hardest for the cell to repair accurately. People who carry inherited defects in repair genes, such as BRCA1 or BRCA2 mutations, are less able to fix this type of damage, which partly explains their elevated cancer risk.22PubMed Central. Ionizing radiation-induced DNA injury and damage detection in patients with breast cancer
The Body’s Own Sources of Mutation
Not all cancer-driving mutations come from outside exposures. The body has internal engines of mutation that can contribute substantially to the damage that drives carcinogenesis. One of the best-characterized is the APOBEC family of enzymes, whose normal job is to defend against viruses by editing their DNA. When these enzymes act on the cell’s own genome instead, they introduce a distinctive pattern of mutations that has been recognized across many cancer types. The APOBEC mutational signature is now considered one of the major endogenous sources of cancer mutations.23PubMed Central. Molecular origins of APOBEC-associated mutations in cancer
Cellular senescence, the process by which damaged cells permanently stop dividing, is itself a tumor-suppressive mechanism. But senescent cells do not sit quietly. They secrete a cocktail of inflammatory molecules, growth factors, and tissue-remodeling enzymes collectively known as the senescence-associated secretory phenotype, or SASP. While the senescent cell itself is not dividing, these secretions can push neighboring premalignant cells toward more aggressive behavior. In laboratory experiments, SASP factors like interleukin-6 and interleukin-8 were able to induce EMT and invasive behavior in nearby epithelial cells that were already partway to becoming cancerous.24PLoS Biology. Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor The paradox is stark: a mechanism that stops one cell from becoming cancerous can simultaneously encourage its neighbors to do so.25PubMed Central. The senescence-associated secretory phenotype: the dark side of tumor suppression
An even more dramatic internal event is chromothripsis, in which a chromosome shatters into dozens or hundreds of pieces and is then reassembled in a scrambled order during a single cell division. Rather than accumulating mutations gradually over years, a cell can acquire massive genomic rearrangements in one catastrophic episode. Recent research has identified a specific enzyme, N4BP2, that fragments chromosomes exposed to the cell’s interior, generating both the scrambled chromosomes of chromothripsis and loose circles of DNA called extrachromosomal DNA (ecDNA). These ecDNA circles can carry amplified copies of oncogenes and lack the normal controls that regulate chromosome behavior, giving the cell a potent growth advantage.26PubMed Central. Chromothripsis and ecDNA initiated by N4BP2 nuclease fragmentation of cytoplasm-exposed chromosomes
Heterogeneity Within a Single Tumor
By the time a tumor is large enough to detect, it is rarely a uniform mass of identical cells. Different regions of the same tumor can harbor different mutations, express different genes, and respond differently to treatment. This intratumoral heterogeneity arises because cancer cells continue to mutate and evolve after the initial transformation, branching into genetically distinct subpopulations that compete with each other for space and resources. Studies of liver cancer, for example, have mapped distinct immune cell populations and gene expression patterns across different regions of a single patient’s tumor, finding that a single biopsy can miss much of the tumor’s true genetic diversity.27Nature Communications. Intratumoral heterogeneity and clonal evolution in liver cancer
This diversity matters practically. A treatment that wipes out one subpopulation may leave a resistant subpopulation behind, which then expands to fill the space. It is one of the main reasons cancers relapse after initially responding to therapy. Researchers are increasingly trying to account for this by sampling tumors from multiple sites and using gene-expression signatures derived from heterogeneity measurements to better predict patient outcomes.
Cancer Stem Cells
Within that heterogeneous mass, a small fraction of cells may act as the tumor’s engine of renewal. These so-called cancer stem cells share properties with normal stem cells: they can self-renew indefinitely and produce the various cell types found in the tumor. The rest of the cancer cells, by contrast, have a limited capacity to divide. Growing evidence suggests that the same genetic pathways governing self-renewal in healthy tissues are hijacked in cancer stem cells, leading to a self-sustaining pool that can regenerate the tumor even after most of its cells have been destroyed by treatment.28PubMed. Self-renewal and solid tumor stem cells If this model is correct, therapies that shrink a tumor without eliminating its stem cell compartment may be removing the bulk but leaving the seed.
What Large Animals Can Teach Us
If cancer results from accumulated mutations in dividing cells, you would expect animals with vastly more cells and longer lifespans to develop cancer far more often than humans. They do not. A blue whale has roughly a thousand times more cells than a person, yet whales are not riddled with tumors. This observation, known as Peto’s paradox, suggests that large, long-lived species have evolved extra layers of cancer protection that humans lack.29PubMed Central. Peto’s Paradox: evolution’s prescription for cancer prevention
Researchers have started cataloging the specific strategies these species use. A comparative analysis of 60 mammalian genomes identified nearly 300 genes under strong selection in long-lived species, many related to immune response and DNA repair. Some of the most intriguing findings involve convergent evolution: bowhead whales and naked mole rats, two species famous for their resistance to cancer, share an identical mutation in a gene called LZTS1 that suppresses tumor development when tested in the lab. In cetaceans (whales and dolphins), a mutation in the YAP1 gene appears to boost tumor suppression by altering where the protein sits inside the cell.30PubMed. Natural resistance to cancers in long-lived mammals: genomic mechanisms and experimental evidence to explain Peto’s paradox A systematic review of the field found that no single strategy explains cancer resistance in all large species; instead, different lineages appear to have arrived at different solutions.31PubMed Central. Peto’s paradox: Nature has used multiple strategies to keep cancer at bay while evolving long lifespans and large body masses Understanding those solutions could eventually point toward new approaches for human cancer prevention.